Menu
← Oncology Approval Tracker
FDA DECISION ·
Krazati + cetuximab
adagrasib with cetuximab · Mirati Therapeutics (Bristol Myers Squibb)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic colorectal cancer with FDA test-confirmed KRAS G12C after fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The combination targets KRAS G12C and EGFR signaling together in previously treated colorectal cancer. The FDA lists this indication as withdrawn in September 2026.
What research teams should watch
Verify the exact KRAS variant and all three required chemotherapy exposures; coordinate oral adherence and IV visits.
PRIMARY RECORDS